文献速递关节外科

被忽视的机会:全膝关节置换术前丙型肝炎治疗对术后并发症的影响

A Missed Opportunity: The Impact of Hepatitis C Treatment Prior to Total Knee Arthroplasty on Postoperative Complications.
PubMed 文献 · J Arthroplasty · 2021-12-22

基于行政理赔数据库的回顾性配对队列研究,比较合并与不合并丙型肝炎(HCV)患者全膝关节置换(TKA)术后并发症,并比较术前接受与未接受抗病毒治疗者。HCV患者术后1年、2年假体周围感染和翻修风险更高,术前抗病毒治疗与假体周围感染风险降低相关。

要点

  • HCV患者TKA术后1年假体周围感染率为4.1%,对照组为2.1%(OR 1.58)。
  • HCV患者TKA术后2年假体周围感染率为5.0%,对照组为2.7%(OR 1.55)。
  • HCV患者术前抗病毒治疗者术后1年假体周围感染率为2.1%,未治疗者为4.1%(OR 0.50)。

核心结论

  • 合并HCV的患者在TKA术后发生假体周围感染和翻修的风险显著升高。
  • TKA术前接受抗病毒治疗可显著降低术后假体周围感染风险。

研究设计与样本

  • 回顾性配对队列研究,使用行政理赔数据库,比较合并与不合并HCV患者TKA术后并发症率。
  • 6971例HCV患者按1:4与27884例无HCV对照配对;708例术前接受抗病毒治疗的HCV患者按1:2与1416例未治疗HCV患者配对。
  • 采用多因素逻辑回归比较术后1年和2年的关节并发症率;证据等级为III级。

主要发现

  • HCV组术后1年假体周围感染率为4.1%,对照组为2.1%(OR 1.58);术后2年HCV组为5.0%,对照组为2.7%(OR 1.55)。
  • HCV组术后1年翻修TKA率为2.8%,对照组为1.8%(OR 1.40);术后2年HCV组为4.1%,对照组为2.9%(OR 1.30)。
  • 术前抗病毒治疗的HCV患者术后1年假体周围感染率为2.1%,未治疗者为4.1%(OR 0.50);术后2年治疗组为2.7%,未治疗组为5.1%(OR 0.51)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hepatitis C (HCV) is undertreated and increasing in prevalence. Its influence on outcomes following total knee arthroplasty (TKA) remains unclear. The purpose of this study is to examine the impact of HCV and prearthroplasty antiviral treatment on postoperative complications following TKA. METHODS: A retrospective matched cohort study was conducted using an administrative claims database to compare postoperative complication rates following TKA for (1) patients with vs without HCV and (2) among patients with HCV, patients with antiviral treatment before TKA vs no treatment. In total, 6971 patients with HCV were matched 1:4 with 27,884 controls without HCV, and 708 HCV patients with antiviral treatment before TKA were matched 1:2 with 1416 HCV patients without treatment. Rates of joint complications at 1 and 2 years postoperatively were compared via multivariable logistic regression. RESULTS: The HCV cohort exhibited significantly higher risk of prosthetic joint infection (PJI) than controls at both 1 (4.1 vs 2.1%; odds ratio [OR] 1.58) and 2 years (5.0% vs 2.7%; OR 1.55) postoperatively. Rates of revision TKA were also significantly higher for HCV patients at 1 (2.8% vs 1.8%; OR 1.40) and 2 years (4.1% vs 2.9%; OR 1.30). HCV patients with prearthroplasty antiviral treatment exhibited significantly lower risk of PJI at 1 (2.1% vs 4.1%; OR 0.50) and 2 years (2.7% vs 5.1%, OR 0.51) compared to patients without treatment. CONCLUSION: Patients with HCV have significantly increased risk of PJI and revision arthroplasty following TKA. Antiviral treatment before TKA significantly decreases the risk of PJI postoperatively. LEVEL OF EVIDENCE: Level III.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Ross AJ, Ross BJ, Lee OC, et al. A Missed Opportunity: The Impact of Hepatitis C Treatment Prior to Total Knee Arthroplasty on Postoperative Complications. J Arthroplasty. 2021. PMID: 34954018. doi:10.1016/j.arth.2021.12.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。